FDA D.I.S.C.O. Burst Edition: FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
0:00
3:30
Listen to a soundcast of the August 10, 2021 FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma
More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Don't miss an episode of “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” and subscribe to it in the GetPodcast app.